Vilamakitug for active axial spondyloarthritis
Part of Bones, joints & muscles clinical trials.
This study tests a new medication called vilamakitug for people with active axial spondyloarthritis. It aims to see if the drug can reduce pain and inflammation better than a placebo (a dummy treatment).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old and weigh more than 88 pounds (40 kg).
- You have been diagnosed with axial spondyloarthritis (a type of arthritis that mainly affects the spine and pelvic joints).
- Your disease is active, meaning you have ongoing pain, stiffness, or swelling that limits your daily activities.
- You have tried at least one NSAID (like ibuprofen or naproxen) and it didn't work well enough.
- You have never used a biologic medication, or you have tried only one, and it's been at least 12 weeks since you stopped it.
- You have never taken a JAK or TYK2 inhibitor (another type of arthritis medication).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication called LNK01001 for adults with active ankylosing spondylitis. It aims to reduce pain, stiffness, and inflammation when standard NSAID treatments no longer help.
This study tests a new medication (called 608) for adults with active ankylosing spondylitis (AS). It aims to see if the drug can reduce AS symptoms and improve quality of life.
This trial tests an investigational medication called SCT650C for people with active axial spondyloarthritis. It aims to see if it can reduce pain and inflammation better than current treatments.
This study tests whether a pain-relief medication called acemetacin works well and is safe for people with axial spondyloarthritis, a type of inflammatory spine condition. Researchers will track your symptoms and side effects over time in a real-world setting.
This trial tests whether tofacitinib (a pill that reduces inflammation) can help people with early-stage axial spondyloarthritis, a type of arthritis that mainly affects the spine and pelvis. It's for those who have had symptoms for 2 years or less and have active disease with signs of inflammation in MRI or blood tests.
This trial tests whether a noninvasive device that stimulates the vagus nerve can reduce symptoms in people with axial spondyloarthritis that hasn’t improved enough with standard medicines and biologic drugs. It may help lower pain and disease activity for those with “treatment-resistant” disease.
Hear when a new Axial Spondyloarthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.